dipivaloylmethane: chelating agent for cadmium; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 70700 |
| CHEMBL ID | 3186481 |
| SCHEMBL ID | 93393 |
| MeSH ID | M0063053 |
| Synonym |
|---|
| 2,6,6-tetramethyl-3,5-heptanedione |
| nsc-174296 |
| 1118-71-4 |
| nsc174296 |
| dipivaloylmethane |
| 3, 2,2,6,6-tetramethyl- |
| 3,5-heptanedione, 2,2,6,6-tetramethyl- |
| 2,2,6,6-tetramethyl-3,5-heptanedione, >=98% |
| 2,2,6,6-tetramethylheptane-3,5-dione |
| D1678 |
| 2,2,6,6-tetramethyl-3,5-heptanedione |
| AKOS000120515 |
| A802429 |
| cas-1118-71-4 |
| NCGC00260268-01 |
| dtxsid7049396 , |
| dtxcid4029355 |
| tox21_202720 |
| 2,2,6,6-tetramethyl-heptane-3,5-dione |
| einecs 214-268-3 |
| unii-r8ui909hoy |
| nsc 174296 |
| r8ui909hoy , |
| FT-0625291 |
| GC10220 |
| AM20080065 |
| BP-21179 |
| SCHEMBL93393 |
| mfcd00008848 |
| SY010005 |
| 2,2,6,6 tetramethyl 3,5 heptanedione |
| 2,2,6,6,-tetramethyl-3,5-heptanedione |
| 2,2,6,6-tetramethyl-3,5-heptandione |
| 2,2,6,6-tetramethyl 3,5-heptanedione |
| tetramethyl heptane 3,5-dione |
| tmhd |
| 2,2,6,6-tetramethyl-3.5-heptanedione |
| 2,2,6,6-tetramethyl-3,5-heptandion |
| 2,2,6,6-tetramethyl-3,5-heptane dione |
| 2,2,6,6 tetramethyl-3,5-heptanedione |
| 2, 2, 6, 6-tetramethylheptane-3,5-dione |
| STR03983 |
| 3,5-heptanedione,2,2,6,6-tetramethyl- |
| 2,2,6,6-tetramethyl heptanedione |
| (ch3)3ccoch2coc(ch3)3 |
| AC-26289 |
| CHEMBL3186481 |
| J-506773 |
| 2,2,6,6-tetramethyl-3,5-heptanedione, for gc derivatization, >=98.0% |
| CS-W008804 |
| BCP22520 |
| Q27287980 |
| EN300-20967 |
| HY-34417 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 19.4167 | 0.0002 | 21.2231 | 8,912.5098 | AID743036 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 68.3477 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 66.4361 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.02) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||